Sprint Bioscience

- Springt Bioscience need to secure and replace some earlier pharma partners. 
- Sprint Bioscience has not yet achieved break-even sales 
- Spring Bioscience remains a small business with limited resources.

- Sprint Bioscience operates very close to its customers and business partners
- Sprint Bioscience can secure milestones, royalties and sometimes recurring sales at a very early stage
- Sprint Bioscience is transparent both in terms of its business and the performance

- Sprint Bioscience has not reached break-even
- Sprint Bioscience need to secure additional partners during 2025
- Candidates are in the discovery phase with a long time to actual commercial sales

- Sprint Bioscience operates very close to its customers and business partners
- Sprint Bioscience can secure milestones, royalties and sometimes recurring sales at a very early stage
- Sprint Bioscience is transparent, and it has secured recurring sales that cover most of its OPEX

- Sprint Bioscience has a different method and approach to drug desovery
- Spring Bioscience has demonstrated the ability to secure royalties and milestones early in the process. 
- Sprint Bioscience has demonstrated the ability to secure contracted recurring discovery services.